(NASDAQ: BCYC) Bicycle Therapeutics's forecast annual revenue growth rate of 35.95% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.98%.
Bicycle Therapeutics's revenue in 2025 is $25,722,000.On average, 4 Wall Street analysts forecast BCYC's revenue for 2025 to be $2,426,311,928, with the lowest BCYC revenue forecast at $1,297,818,911, and the highest BCYC revenue forecast at $2,970,994,198. On average, 4 Wall Street analysts forecast BCYC's revenue for 2026 to be $2,660,805,782, with the lowest BCYC revenue forecast at $808,886,066, and the highest BCYC revenue forecast at $3,565,193,037.
In 2027, BCYC is forecast to generate $4,897,846,682 in revenue, with the lowest revenue forecast at $2,946,062,778 and the highest revenue forecast at $7,969,743,876.